Canada Post Corp Registered Pension Plan Has $11.50 Million Position in AbbVie Inc. $ABBV

Canada Post Corp Registered Pension Plan raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 49.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,532 shares of the company’s stock after purchasing an additional 17,052 shares during the quarter. Canada Post Corp Registered Pension Plan’s holdings in AbbVie were worth $11,500,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ABBV. Vanguard Group Inc. boosted its stake in AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after purchasing an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after buying an additional 1,517,222 shares during the last quarter. Norges Bank bought a new stake in AbbVie during the second quarter worth $4,288,200,000. Finally, Raymond James Financial Inc. grew its holdings in AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

AbbVie Trading Up 2.0%

Shares of NYSE ABBV opened at $223.50 on Friday. The stock has a fifty day simple moving average of $223.74 and a two-hundred day simple moving average of $219.41. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The firm has a market cap of $395.01 billion, a price-to-earnings ratio of 94.70, a price-to-earnings-growth ratio of 0.89 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ABBV. Raymond James Financial set a $256.00 price objective on AbbVie in a research note on Monday, November 3rd. UBS Group lowered their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday. Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. Finally, Evercore decreased their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.